Dr. Sarah Trice started her career as a medicinal chemist at Merck & Co. working to discover and develop novel HIV therapies. She later joined Merck KGaA and held a series of leadership positions to support the development and commercialization of enabling technologies for the pharmaceutical industry, notably leading the acquisition and development of SYNTHIA, an AI-powered retrosynthesis SaaS. After completing her MBA from MIT’s Sloan School, Sarah was a co-founder and COO of Iambic, a small molecule oncology drug discovery company at the intersection of AI and automation. Sarah currently serves as the COO, Head of US Operations for XtalPi, a technology development company specializing in AI and automation for drug discovery. She holds a PhD in organic chemistry from the University of Pennsylvania.